BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 35153138)

  • 1. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.
    Zeng J; Qin L; Jin Q; Yang RX; Ning G; Su Q; Yang Z; Fan JG
    Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):154-161. PubMed ID: 35153138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.
    Liu Q; Zhao G; Li Q; Wu W; Zhang Y; Bian H
    BMC Gastroenterol; 2022 Nov; 22(1):471. PubMed ID: 36402947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
    Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
    Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
    Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease.
    Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.
    Cho Y; Chang Y; Ryu S; Wild SH; Byrne CD
    Liver Int; 2023 Nov; 43(11):2445-2454. PubMed ID: 37387519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
    Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
    Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
    Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
    Kemp W; Clayton-Chubb D; Majeed A; Glenister KM; Magliano DJ; Lubel J; Bourke L; Simmons D; Roberts SK
    J Gastroenterol Hepatol; 2022 Feb; 37(2):395-403. PubMed ID: 34693553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.